PEAK6
TEVA icon

PEAK6’s Teva Pharmaceuticals TEVA Stock Holding History

PEAK6’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Hold
100,000
– – 0.01% 1160
2025
Q4 		$3.12M Hold
100,000
– – 0.01% 1188
2025
Q3 		$2.02M Hold
100,000
– – ﹤0.01% 1499
2025
Q2 		$1.68M Buy
+100,000
New +$1.61M ﹤0.01% 1541

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6's TEVA Position: Q4 2025 in Review

PEAK6 sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 4,763 shares — an estimated $117K sold.

PEAK6 first reported a position in TEVA in Q2 2025 and held it in 2 quarters. The position peaked at $151K in Q2 2025. 629 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • PEAK6 reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PEAK6 sold 4,763 Teva Pharmaceuticals shares in Q4 2025, an estimated $117K.
  • PEAK6 first reported a position in Teva Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • PEAK6's Teva Pharmaceuticals position peaked at $151K in Q2 2025.
  • 629 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on PEAK6's 13F filing for Q4 2025, filed 13 Feb 2026.